Albireo to Present Clinical Data on A4250 in Alagille Syndrome and Biliary Atresia at The International Liver Congress™ 201...
March 27 2019 - 8:48AM
Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan
pediatric liver disease company developing novel bile acid
modulators, today announced that results from its completed Phase 2
clinical trial of lead product candidate A4250 in children with
Alagille syndrome and biliary atresia have been selected for
presentation at the European Association for the Study of the Liver
(EASL) The International Liver Congress (ILC) 2019, being held
April 10-14, 2019, at the Reed Messe Wien Exhibition & Congress
Center in Vienna, Austria.
The Phase 2 trial evaluated A4250 in children with cholestatic
liver diseases including Alagille syndrome and biliary atresia.
Trial results for patients with Alagille syndrome have been
selected for an oral presentation on Saturday, April 13, and
results for patients with biliary atresia will be presented during
a poster session on Friday, April 12.
Details of the presentations are as follows:
Title: Effects of the ileal bile acid transport
inhibitor A4250 on serum bile acids, pruritus and sleep in patients
with Alagille syndrome: Phase 2 study resultsPresentation
Number: PS-194Session: Parallel session:
Clinical developments in rare liver diseaseDate /
Time: Saturday, April 13, 8:30 a.m.
CESTPresenter: Dr. Ulrich Baumann, Professor of
Pediatric Gastroenterology and Hepatology, Hannover Medical School;
Hannover, Germany
Title: Effects of the ileal bile acid transport
inhibitor A4250 on pruritus and serum bile acids inpatients with
biliary atresia: Phase 2 study resultsPresentation
Number: FRI-060Session: Poster:
Autoimmune and chronic cholestatic liver disease: Clinical
aspectsDate / Time: Friday, April 12, 9 a.m. - 5
p.m. CESTPresenter: Dr. Ekkehard Sturm, Head of
Pediatric Gastroenterology-Hepatology, Liver and Intestinal
Transplantation, Children's Hospital, University of Tuebingen;
Tuebingen, Germany
Also at EASL, the following presentation by Daan van Wessel,
University Medical Center Groningen, Netherlands, on April 13 at
8:45 a.m. CEST is relevant to the development of A4250: “Predicting
long-term outcome after surgical biliary diversion in
BSEP-deficiency patients: Results from the NAPPED consortium”
(presentation number PS-195). Notably, the NAPPED consortium data
demonstrate the impact of surgical biliary diversion on serum bile
acids in bile salt export pump (BSEP)-deficient patients with mild
or moderate PFIC type 2. NAPPED is supported by an unrestricted
grant from Albireo.
The International Liver Congress is the annual EASL meeting,
which brings together more than 10,000 scientific and medical
experts from around the world to learn about the latest in liver
research. For more information about the conference, visit
https://ilc-congress.eu/.
About Albireo Albireo Pharma is a
clinical-stage biopharmaceutical company focused through its
operating subsidiary on the development of novel bile acid
modulators to treat orphan pediatric liver diseases, and other
liver and gastrointestinal diseases and disorders. Albireo’s lead
product candidate, A4250, is being developed to treat rare
pediatric cholestatic liver diseases and is in Phase 3 development
in its initial target indication, progressive familial intrahepatic
cholestasis. Albireo’s clinical pipeline also includes two Phase 2
product candidates. Albireo’s elobixibat, approved
in Japan for the treatment of chronic constipation, is
the first ileal bile acid transporter (IBAT) inhibitor
approved anywhere in the world. Albireo was spun out
from AstraZeneca in 2008.
Albireo Pharma is located
in Boston, Massachusetts, and its key operating
subsidiary is located in Gothenburg, Sweden. For more
information on Albireo, please
visit www.albireopharma.com.
Investor Contact: Hans Vitzthum, LifeSci
Advisors, LLC,
212-915-2568
Media Contact: Heather Anderson, 6 Degrees,
980-938-0260, handerson@6degreespr.com
Source: Albireo Pharma, Inc.
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From Sep 2023 to Sep 2024